Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth
NEW YORK, Oct. 25, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
http://www.reportlinker.com/p0660752/Neurodegenerative-Disease-Market-to-2017---Patent-Expiries-of-High-Selling-Drugs-Such-as-Aricept-Namenda-Avonex-Rebif-and-Copaxone-will-Restrain-Growth.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth
Summary
GBI Research, the leading business intelligence provider, has released its latest research "Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth", which provides insights into the Neurodegenerative Disease Market until 2017. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. The report provides an in-depth analysis of the major neurodegenerative disease including Alzheimer's disease, Multiple sclerosis, Parkinson disease, Diabetic neuropathy and also orphan neurodegenerative diseases such as Huntington's disease and Amyotrophic lateral sclerosis. The report also provides information on the share of generics in Neurodegenerative Disease Markets and examines the global treatment usage patterns for neurodegenerative diseases. In addition, the geographical distribution of neurodegenerative diseases and therapeutics market across the US, the top five countries of Europe and in Japan. The report also includes insights into the neurodegenerative disease therapeutics research and development (R&D) product pipeline and explores the competitive landscape, including major players in the Neurodegenerative Disease Market. Finally, the report also includes analysis of the Mergers and Acquisitions (M&As) and licensing agreements that have taken place in the Neurodegenerative Disease Market.
Scope
- The report analyzes treatment usage patterns, market characterization, pipeline analysis, competitive landscape and key M&A trends in the global neurodegenerative disease market for the six indications that includes Alzheimer's disease, Multiple sclerosis, Parkinson's disease, Diabetic neuropathy and orphan neurodegenerative disease such as Huntington's disease and Amyotrophic lateral sclerosis.
- Data and analysis on the neurodegenerative disease market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.
- Annualized market data for the neurodegenerative disease market from 2002 to 2010, with market forecasts to 2017.
- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
- Share of the generics in global neurodegenerative disease market and for the market of each indication that are covered in the report.
- Key drivers and restraints that have had a significant impact on the market.
- The competitive landscape of the global neurodegenerative disease market including top companies benchmarking. The key companies studied in this report are Teva, Novartis, Merck, Pfizer and Boehringer Ingelheim, Bayer Schering and Biogen Idec.
- Key M&A activities and Licensing Agreements that took place in 2009 and 2010 in the neurodegenerative disease market.
Reasons to buy
The report will assist business development and marketing executives to strategize their product launches, by allowing them to -
- Align your product portfolio to the markets with high growth potential.
- Build effective strategies to launch their pipeline products by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Device a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication.
- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 10
2 Neurodegenerative Disease Market to 2017 - Introduction 12
2.1 GBI Research Report Guidance 13
3 Neurodegenerative Disease Market to 2017 – Global Market Overview 14
3.1 Introduction 14
3.2 Revenue 16
3.2.1 Generic Share 17
3.2.2 Annual Cost of Treatment 18
3.2.3 Treatment Usage Patterns 19
4 Neurodegenerative Disease Market to 2017 – Geographical Landscape 21
4.1 The US 23
4.1.1 Revenue 23
4.1.2 Annual Cost of Treatment 24
4.1.3 Treatment Usage Patterns 25
4.2 Top Five Countries of Europe 27
4.2.1 Annual Cost of Treatment 28
4.2.2 Treatment Usage Patterns 29
4.3 Japan 31
4.3.1 Annual Cost of Treatment 32
4.3.2 Treatment Usage Patterns 33
5 Neurodegenerative Disease Market to 2017 – Therapeutic Landscape 35
5.1 Alzheimer's Disease Therapeutics Market 35
5.1.1 Introduction 35
5.1.2 Revenue 36
5.1.3 Annual Cost of Treatment 40
5.1.4 Treatment Usage Patterns 41
5.2 Drivers and Restraints to the Alzheimer's Disease Therapeutics Market 43
5.2.1 Drivers for Alzheimer's Disease Therapeutics Market 43
5.2.2 Restraints for Alzheimer's Disease Therapeutics Market 44
5.3 Multiple Sclerosis Market 44
5.3.1 Introduction 44
5.3.2 Revenue 45
5.3.3 Annual Cost of Treatment 49
5.3.4 Treatment Usage Patterns 50
5.4 Drivers and Restraints to Multiple Sclerosis Market 52
5.4.1 Drivers for Multiple Sclerosis Market 52
5.4.2 Restraints for Multiple Sclerosis Market 53
5.5 Parkinson's Disease Therapeutics Market 53
5.5.1 Introduction 53
5.5.2 Revenue 53
5.5.3 Annual Cost of Treatment 57
5.5.4 Treatment Usage Patterns 58
5.6 Drivers and Restraints to Parkinson's Disease Therapeutics Market 60
5.6.1 Drivers for the Parkinson's Disease Therapeutics Market 60
5.6.2 Restraints for the Parkinson's Disease Therapeutics Market 60
5.7 Diabetic Neuropathy Market 61
5.7.1 Introduction 61
5.7.2 Revenue 61
5.7.3 Annual Cost of Treatment 65
5.7.4 Treatment Usage Pattern 66
5.8 Drivers and Restraints to Diabetic Neuropathy Therapeutics Market 68
5.8.1 Drivers for Diabetic Neuropathy Market 68
5.8.2 Restraints for the Diabetic Neuropathy Therapeutics Market 69
5.9 Huntington's Disease Market 69
5.9.1 Introduction 69
5.9.2 Revenue 70
5.9.3 Annual Cost of Treatment 73
5.9.4 Treatment Usage Pattern 74
5.10 Drivers and Restraints to the Market for Huntington's Disease 76
5.10.1 Drivers for Huntington's Disease 76
5.10.2 Restraints for Huntington's Disease 77
5.11 Amyotrophic Lateral Sclerosis (ALS) Market /Lou Gehrig's Disease 77
5.11.1 Introduction 77
5.11.2 Revenue 78
5.11.3 Annual Cost of Treatment 82
5.11.4 Treatment Usage Patterns 83
5.12 Drivers and Restraints to Amyotrophic Lateral Sclerosis Market 85
5.12.1 Drivers for Amyotrophic Lateral Sclerosis Market 85
5.12.2 Restraints for Amyotrophic Lateral Sclerosis Market 86
6 Neurodegenerative Disease Market to 2017 – Product Pipeline Analysis 87
6.1 Introduction 87
6.1.1 Alzheimer's disease 88
6.1.2 Diabetic Neuropathy 101
6.1.3 Multiple Sclerosis 103
6.1.4 Parkinson's disease 108
6.1.5 ALS 115
6.1.6 Huntington's disease 117
7 Neurodegenerative Disease Market to 2017 – Competitive Landscape 120
7.1 Market Share Analysis 120
7.2 Teva 121
7.2.1 Company overview 121
7.2.2 SWOT Analysis 121
7.3 Biogen Idec 122
7.3.1 Company Overview 122
7.3.2 SWOT Analysis 122
7.4 Merck Serono 123
7.4.1 Company Overview 123
7.4.2 SWOT Analysis 123
7.5 Bayer Schering Pharma AG 124
7.5.1 Company Overview 124
7.5.2 SWOT Analysis 124
7.6 Novartis 125
7.6.1 Company Overview 125
7.6.2 SWOT Analysis 125
7.7 Boehringer Ingelheim 126
7.7.1 Company Overview 126
7.7.2 SWOT Analysis 126
7.8 Pfizer 127
7.8.1 Company Overview 127
7.8.2 SWOT Analysis 127
8 Neurodegenerative Disease Market to 2017 – M&A Landscape 128
8.1 M&A Deals (2009-2010) 128
8.1.1 M&A Deals by Region 130
8.1.2 M&A Deals by Value 131
8.1.3 Deal Summary of Top 10 M&A Deals by Value 131
8.2 Licensing Deals 134
8.2.1 Deal Summary 135
9 Neurodegenerative Disease Market to 2017 – Appendix 138
9.1 Market Definitions 138
9.2 Abbreviations 138
9.3 Research Methodology 139
9.3.1 Coverage 139
9.3.2 Secondary Research 140
9.3.3 Primary Research 140
9.3.4 Therapeutic Landscape 141
9.3.5 Geographical Landscape 144
9.3.6 Pipeline Analysis 144
9.3.7 Competitive Landscape 144
9.3.8 Expert Panel Validation 144
9.4 Contact Us 144
9.5 Disclaimer 144
9.6 Sources 145
1.1 List of Tables
Table 1: Neurodegenerative Disease Market, Global, Revenue ($m), 2002-2010 16
Table 2: Neurodegenerative Disease Market, Global, Revenue Forecasts ($m), 2010-2017 16
Table 3: Neurodegenerative Disease Market, Global, Annual Cost of Treatment ($), 2002-2010 18
Table 4: Neurodegenerative Disease Market, Global, Annual Cost of Treatment ($), 2010-2017 18
Table 5: Neurodegenerative Disease Market, Global, Treatment Usage Patterns (Thousand), 2002-2010 19
Table 6: Neurodegenerative Disease Market, Global, Treatment Usage Patterns (thousand), 2010-2017 20
Table 7: Neurodegenerative Disease Market, Global Revenue by Country ($m), 2002-2010 22
Table 8: Neurodegenerative Disease Market, Global Revenue by Country ($m), 2010-2017 22
Table 9: Neurodegenerative Disease Market, The US, Revenue ($m), 2002-2010 23
Table 10: Neurodegenerative Disease Market, The US, Revenue Forecasts ($m), 2010-2017 23
Table 11: Neurodegenerative Disease Market, The US, Annual Cost of Treatment ($), 2002-2010 24
Table 12: Neurodegenerative Disease Market, The US, Annual Cost of Treatment ($), 2010-2017 24
Table 13: Neurodegenerative Disease Market, The US, Treatment Usage Patterns (thousand), 2002-2010 25
Table 14: Neurodegenerative Disease Market, The US, Treatment Usage Patterns (thousand), 2010-2017 26
Table 15: Neurodegenerative Disease Market, Top Five Countries of Europe, Revenue ($m), 2002-2010 27
Table 16: Neurodegenerative Disease Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2010-2017 27
Table 17: Neurodegenerative Disease Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2010 28
Table 18: Neurodegenerative Disease Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2010-2017 28
Table 19: Neurodegenerative Disease Market, Top Five Countries of Europe, Treatment Usage Pattern (thousand), 2002-2010 29
Table 20: Neurodegenerative Disease Market, Top Five Countries of Europe, Treatment Usage Patterns (Thousand), 2010-2017 30
Table 21: Neurodegenerative Disease Market, Japan, Revenue ($m), 2002-2010 31
Table 22: Neurodegenerative Disease Market, Japan, Revenue Forecasts ($m), 2010-2017 31
Table 23: Neurodegenerative Disease Market, Japan, Annual Cost of Treatment ($), 2010-2017 32
Table 24: Neurodegenerative Disease Market, Japan, Annual Cost of Treatment ($), 2010-2017 32
Table 25: Neurodegenerative Disease Market, Japan, Treatment Usage Patterns (thousand), 2002-2010 33
Table 26: Neurodegenerative Disease Market, Japan, Treatment Usage Patterns (thousand), 2010-2017 34
Table 27: Neurodegenerative Disease Market, Alzheimer's Disease, FDA Approved Cholinesterase Inhibitors, 2010 36
Table 28: Neurodegenerative Disease Market, Alzheimer's Disease, Global Revenue ($bn), 2002-2010 37
Table 29: Neurodegenerative Disease Market, Alzheimer's Disease, Global Revenue Forecasts ($bn), 2010-2017 37
Table 30: Neurodegenerative Disease Market, Alzheimer's Disease, Revenue by Country ($m), 2002-2010 38
Table 31: Neurodegenerative Disease Market, Alzheimer's Disease, Revenue by Country ($m), 2010-2017 39
Table 32: Neurodegenerative Disease Market, Alzheimer's Disease, Annual Cost of Treatment ($), 2002-2010 40
Table 33: Neurodegenerative Disease Market, Alzheimer's Disease, Annual Cost of Treatment ($), 2010-2017 40
Table 34: Neurodegenerative Disease Market, Alzheimer's Disease, Global Treatment Usage Pattern (Thousand), 2002-2010 41
Table 35: Neurodegenerative Disease Market, Alzheimer's Disease, Global Treatment Usage Pattern (Thousand), 2010-2017 42
Table 36: Neurodegenerative Disease Market, Multiple Sclerosis, Global Revenue ($m), 2002-2010 46
Table 37: Neurodegenerative Disease Market, Multiple Sclerosis, Global Revenue Forecasts ($m), 2010-2017 47
Table 38: Neurodegenerative Disease Market, Multiple Sclerosis, Revenue by Country ($m), 2002-2010 47
Table 39: Neurodegenerative Disease Market, Multiple Sclerosis, Revenue by Country ($m), 2010-2017 48
Table 40: Neurodegenerative Disease Market, Multiple Sclerosis, Annual Cost of Treatment ($), 2002-2010 49
Table 41: Neurodegenerative Disease Market, Multiple Sclerosis, Annual Cost of Treatment ($), 2010-2017 49
Table 42: Neurodegenerative Disease Market, Multiple Sclerosis, Global Treatment Usage Pattern (Thousand), 2002-2010 50
Table 43: Neurodegenerative Disease Market, Multiple Sclerosis, Global Treatment Usage Pattern (Thousand), 2010-2017 51
Table 44: Neurodegenerative Disease Market, Parkinson's disease, Global Revenue ($m), 2002-2010 54
Table 45: Neurodegenerative Disease Market, Parkinson's disease, Global Revenue Forecasts ($m), 2010-2017 54
Table 46: Neurodegenerative Disease Market, Parkinson's Disease, Revenue by Country ($m), 2002-2010 55
Table 47: Neurodegenerative Disease Market, Parkinson's Disease, Revenue by Country ($m), 2010-2017 56
Table 48: Neurodegenerative Disease Market, Parkinson's Disease, Annual Cost of Treatment ($), 2002-2010 57
Table 49: Neurodegenerative Disease Market, Parkinson's Disease, Annual Cost of Treatment ($), 2010-2017 57
Table 50: Neurodegenerative Disease Market, Parkinson's Disease, Global Treatment Usage Pattern (Thousand), 2002-2010 58
Table 51: Neurodegenerative Disease Market, Parkinson's Disease, Global Treatment Usage Pattern (Thousand), 2010-2017 59
Table 52: Neurodegenerative Disease Market, Diabetic Neuropathy, Global Revenue ($m), 2002-2010 62
Table 53: Neurodegenerative Disease Market, Diabetic Neuropathy, Global Revenue Forecasts ($m), 2010-2017 62
Table 54: Neurodegenerative Disease Market, Diabetic Neuropathy, Revenue by Country ($m), 2002-2010 63
Table 55: Neurodegenerative Disease Market, Diabetic Neuropathy, Revenue by Country ($m), 2010-2017 64
Table 56: Neurodegenerative Disease Market, Diabetic Neuropathy, Annual Cost of Treatment ($), 2002-2010 65
Table 57: Neurodegenerative Disease Market, Diabetic Neuropathy, Annual Cost of Treatment ($), 2010-2017 65
Table 58: Neurodegenerative Disease Market, Diabetic Neuropathy, Global Treatment Usage Pattern (Thousand), 2002-2010 66
Table 59: Neurodegenerative Disease Market, Diabetic Neuropathy, Global Treatment Usage Pattern (Thousand), 2010-2017 67
Table 60: Neurodegenerative Disease Market, Huntington's Disease, Global Revenue ($m), 2002-2010 70
Table 61: Neurodegenerative Disease Market, Huntington's Disease, Global Revenue Forecast ($m), 2010-2017 70
Table 62: Neurodegenerative Disease Market, Huntington's Disease, Revenue by Country ($'000),2002-2010 71
Table 63: Neurodegenerative Disease Market, Huntington's Disease, Revenue by Country ($'000),2010-2017 72
Table 64: Neurodegenerative Disease Market, Huntington's Disease, Annual Cost of Treatment ($), 2002-2010 73
Table 65: Neurodegenerative Disease Market, Huntington's Disease, Annual Cost of Treatment ($), 2010-2017 73
Table 66: Neurodegenerative Disease Market, Huntington's Disease, Global Treatment Usage Pattern (Thousand), 2002-2010 74
Table 67: Neurodegenerative Disease Market, Huntington's Disease, Global Treatment Usage Pattern (Thousand), 2010-2017 75
Table 68: Neurodegenerative Disease Market, Amyotrophic Lateral Sclerosis, Global Revenue ($m), 2002-2010 79
Table 69: Neurodegenerative Disease Market, Amyotrophic Lateral Sclerosis, Global Revenue Forecasts ($m), 2010-2017 79
Table 70: Neurodegenerative Disease Market, Amyotrophic Lateral Sclerosis, Revenue by Country ($'000),2002-2010 80
Table 71: Neurodegenerative Disease Market, Amyotrophic Lateral Sclerosis, Revenue by Country ($'000),2010-2017 81
Table 72: Neurodegenerative Disease Market, Amyotrophic Lateral Sclerosis, Annual Cost of Treatment ($), 2002-2010 82
Table 73: Neurodegenerative Disease Market, Amyotrophic Lateral Sclerosis, Annual Cost of Treatment ($), 2010-2017 82
Table 74: Neurodegenerative Disease Market, Amyotrophic Lateral Sclerosis, Global Treatment Usage Pattern (thousand), 2002-2010 83
Table 75: Neurodegenerative Disease Market, Amyotrophic Lateral Sclerosis, Global Treatment Usage Pattern (thousand), 2002-2010 84
Table 76: Neurodegenerative Disease Market, Alzheimer's Disease, Discovery Product Pipeline, 2010 88
Table 77: Neurodegenerative Disease Market, Diabetic Neuropathy, Product Pipeline, 2010 101
Table 78: Neurodegenerative Disease Market, Multiple Sclerosis, Product Pipeline, 2010 103
Table 79: Neurodegenerative Disease Market, Parkinson's Disease, Product Pipeline, 2010 109
Table 80: Neurodegenerative Disease Market, ALS Product Pipeline, 2010 115
Table 81: Neurodegenerative Disease Market, HD Product Pipeline, 2010 118
Table 82: Neurodegenerative Disease Market, Global, M&A Deals, 2009-2010 128
Table 83: Neurodegenerative Disease Market, Global, Top Licensing Deals by Value ($m), 2009-2010 134
1.2 List of Figures
Figure 1: Neurodegenerative Disease Market, Global, Share of Neurodegenerative Disease (%), 2010 14
Figure 2: Neurodegenerative Disease Market, Global, Revenue Forecasts ($m), 2002-2017 16
Figure 3: Neurodegenerative Disease Market, Global, Generic Share in Global Neurodegenerative Disease Market,(%), 2010, 2017 17
Figure 4: Neurodegenerative Disease Market, Global, Annual Cost of Treatment ($), 2002-2017 18
Figure 5: Neurodegenerative Disease Market, Global, Treatment Usage Patterns (Thousand), 2002-2017 19
Figure 6: Neurodegenerative Disease Market, Global Revenue by Country ($m), 2002-2017 21
Figure 7: Neurodegenerative Disease Market, The US, Revenue Forecasts ($m), 2002-2017 23
Figure 8: Neurodegenerative Disease Market, The US, Annual Cost of Treatment ($), 2002-2017 24
Figure 9: Neurodegenerative Disease Market, The US, Treatment Usage Patterns (thousand), 2002-2017 25
Figure 10: Neurodegenerative Disease Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2002-2017 27
Figure 11: Neurodegenerative Disease Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2017 28
Figure 12: Neurodegenerative Disease Market, Top Five Countries of Europe, Treatment Usage Patterns (Thousand), 2002-2017 29
Figure 13: Neurodegenerative Disease Market, Japan, Revenue Forecasts ($m), 2002-2017 31
Figure 14: Neurodegenerative Disease Market, Japan, Annual Cost of Treatment ($), 2002-2017 32
Figure 15: Neurodegenerative Disease Market, Japan, Treatment Usage Patterns (thousand), 2002-2017 33
Figure 16: Neurodegenerative Disease Market, Alzheimer's Disease, Global Revenue Forecasts ($bn), 2002-2017 37
Figure 17: Neurodegenerative Disease Market, Alzheimer's Disease, Revenue by Country ($m), 2002-2017 38
Figure 18: Neurodegenerative Disease Market, Alzheimer's Disease, Generic Share in Alzheimer's Disease Therapeutics Market, 2010, 2017 39
Figure 19: Neurodegenerative Disease Market, Alzheimer's Disease, Annual Cost of Treatment ($), 2002-2017 40
Figure 20: Neurodegenerative Disease Market, Alzheimer's Disease, Global Treatment Usage Pattern (Thousand), 2002-2017 41
Figure 21: Neurodegenerative Disease Market, Alzheimer's Disease, Global Market Drivers and Restraints, 2010-2017 43
Figure 22: Neurodegenerative Disease Market, Multiple Sclerosis, Global Revenue Forecasts ($m), 2002-2017 46
Figure 23: Neurodegenerative Disease Market, Multiple Sclerosis, Revenue by Country ($m), 2002-2017 47
Figure 24: Neurodegenerative Disease Market, Multiple Sclerosis, Generic Share in Multiple Sclerosis Market, (%), 2010, 2017 48
Figure 25: Neurodegenerative Disease Market, Multiple Sclerosis, Annual Cost of Treatment ($), 2002-2017 49
Figure 26: Neurodegenerative Disease Market, Multiple Sclerosis, Global Treatment Usage Pattern (Thousand), 2002-2017 50
Figure 27: Neurodegenerative Disease Market, Multiple Sclerosis, Global Market Drivers and Restraints, 2010-2017 52
Figure 28: Neurodegenerative Disease Market, Parkinson's Disease, Global Revenue Forecasts ($m), 2002-2017 54
Figure 29: Neurodegenerative Disease Market, Parkinson's Disease, Revenue by Country ($m), 2002-2017 55
Figure 30: Neurodegenerative Disease Market, Parkinson's Disease, Generic Share in Parkinson's disease Market, ($m) 2010, 2017 56
Figure 31: Neurodegenerative Disease Market, Parkinson's Disease, Annual Cost of Treatment ($), 2002-2017 57
Figure 32: Neurodegenerative Disease Market, Parkinson's Disease, Global Treatment Usage Pattern (Thousand), 2002-2017 58
Figure 33: Neurodegenerative Disease Market, Parkinson's Disease, Global Market Drivers and Restraints, 2010-2017 60
Figure 34: Neurodegenerative Disease Market, Diabetic Neuropathy, Global Revenue Forecasts ($m), 2002-2017 62
Figure 35: Neurodegenerative Disease Market, Diabetic Neuropathy, Revenue by Country ($m), 2002-2017 63
Figure 36: Neurodegenerative Disease Market, Diabetic Neuropathy, Generic Share in Diabetic Neuropathy Market, ($m) 2010,2017 64
Figure 37: Neurodegenerative Disease Market, Diabetic Neuropathy, Annual Cost of Treatment ($), 2002-2017 65
Figure 38: Neurodegenerative Disease Market, Diabetic Neuropathy, Global Treatment Usage Pattern (Thousand), 2002-2017 66
Figure 39: Neurodegenerative Disease Market, Diabetic Neuropathy, Global Market Drivers and Restraints, 2010-2017 68
Figure 40: Neurodegenerative Disease Market, Huntington's Disease, Global Revenue Forecast ($m), 2002-2017 70
Figure 41: Neurodegenerative Disease Market, Huntington's Disease, Revenue by Country ($m),2002-2017 71
Figure 42: Neurodegenerative Disease Market, Huntington's Disease, Generic Share in Huntington's Disease Market, ($m) 2010,2017 72
Figure 43: Neurodegenerative Disease Market, Huntington's Disease, Annual Cost of Treatment ($), 2002-2017 73
Figure 44: Neurodegenerative Disease Market, Huntington's Disease, Global Treatment Usage Pattern (Thousand), 2002-2017 74
Figure 45: Neurodegenerative Disease Market, Huntington's Disease, Global Market Drivers and Restraints, 2010-2017 76
Figure 46: Neurodegenerative Disease Market, Amyotrophic Lateral Sclerosis, Global Revenue Forecasts ($m), 2002-2017 79
Figure 47: Neurodegenerative Disease Market, Amyotrophic Lateral Sclerosis, Revenue by Country ($m),2002-2017 80
Figure 48: Neurodegenerative Disease Market, Amyotrophic Lateral Sclerosis, Generic Share in ALS Market, (%) 2010,2017 81
Figure 49: Neurodegenerative Disease Market, Amyotrophic Lateral Sclerosis, Annual Cost of Treatment ($), 2002-2017 82
Figure 50: Neurodegenerative Disease Market, Amyotrophic Lateral Sclerosis, Global Treatment Usage Pattern (thousand), 2002-2017 83
Figure 51: Neurodegenerative Disease Market, Amyotrophic Lateral Sclerosis, Global Market Drivers and Restraints, 2010-2017 85
Figure 52: Neurodegenerative Disease Market, Global Product Pipeline by Indication (%), 2010 87
Figure 53: Neurodegenerative Disease Market, Global Top Companies Share (%), 2010 120
Figure 54: Neurodegenerative Disease Market, SWOT Analysis, Teva, 2011 121
Figure 55: Neurodegenerative Disease Market, SWOT Analysis, Biogen Idec, 2011 122
Figure 56: Neurodegenerative Disease Market, SWOT Analysis, Merck Serono, 2011 123
Figure 57: Neurodegenerative Disease Market, SWOT Analysis, Bayer Schering, 2011 124
Figure 58: Neurodegenerative Disease Market, SWOT Analysis, Novartis, 2011 125
Figure 59: Neurodegenerative Disease Market, SWOT Analysis, Boehringer Ingelheim, 2011 126
Figure 60: Neurodegenerative Disease Market, SWOT Analysis, Pfizer, 2011 127
Figure 61: Neurodegenerative Disease Market, Global, M&A Deals by Region, 2009-2010 130
Figure 62: Neurodegenerative Disease Market, Global, M&A Deals by Value ($m), 2009-2010 131
Figure 63: GBI Research Market Forecasting Model 143
Companies Mentioned
Teva
Biogen Idec
Merck Serono
Bayer Schering Pharma AG
Novartis
Boehringer Ingelheim
Pfizer
To order this report:
Pathology Industry: Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth
Pathology Business News
Check our Industry Analysis and Insights
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article